Literature DB >> 7616402

Cocaethylene: pharmacology, physiology and behavioral effects in humans.

E F McCance1, L H Price, T R Kosten, P I Jatlow.   

Abstract

Comorbid abuse of cocaine and alcohol is a common occurrence. Cocaethylene, the ethyl ester of benzoylecgonine, is an active metabolite formed as a result of simultaneous use of these substances. In humans, the concurrent ingestion of cocaine and alcohol, with resulting cocaethylene formation, has been associated with enhanced subjective euphoria, increased heart rate and increased plasma cocaine concentration. These findings suggest that cocaethylene may play a role in the morbidity and mortality associated with concurrent cocaine/alcohol abuse. This placebo-controlled, double-blinded study examined the behavioral and physiological effects and pharmacokinetics of intranasal cocaethylene administration in humans (n = 8), using cocaine as a comparator. Cocaethylene administration resulted in a euphoria similar to that produced by cocaine, although the effects differed significantly over time. Subjects were unable to distinguish between equimolar doses of cocaine and cocaethylene, although cocaethylene appeared to be eliminated more slowly than cocaine. Cardiovascular effects of cocaethylene and cocaine were similar. These findings are considered in light of the epidemiology and possible consequences of cocaine and alcohol abuse.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616402

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Neuropsychological effects associated with recreational cocaine use.

Authors:  Kirstie Soar; Colette Mason; Anita Potton; Lynne Dawkins
Journal:  Psychopharmacology (Berl)       Date:  2012-02-29       Impact factor: 4.530

2.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

3.  Disulfiram effects on responses to intravenous cocaine administration.

Authors:  Jennifer R Baker; Peter Jatlow; Elinore F McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2006-09-18       Impact factor: 4.492

4.  Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity.

Authors:  Seungmin Jahng; Timothy J Trull; Phillip K Wood; Sarah L Tragesser; Rachel Tomko; Julia D Grant; Kathleen K Bucholz; Kenneth J Sher
Journal:  J Abnorm Psychol       Date:  2011-08

Review 5.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 6.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

7.  The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice.

Authors:  Hanna N Wetzel; Michael R Tabet; William J Ball; Andrew B Norman
Journal:  Int Immunopharmacol       Date:  2014-12       Impact factor: 4.932

8.  The rate ratio of injury and aggressive incident for alcohol alone, cocaine alone and simultaneous use before the event: a case-crossover study.

Authors:  Jinhui Zhao; Scott Macdonald; Guilherme Borges; Chantele Joordens; Tim Stockwell; Yu Ye
Journal:  Accid Anal Prev       Date:  2014-12-03

Review 9.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

10.  Sex differences in cocaine-dependent individuals' response to disulfiram treatment.

Authors:  Charla Nich; Elinore F McCance-Katz; Ismene L Petrakis; Joseph F Cubells; Bruce J Rounsaville; Kathleen M Carroll
Journal:  Addict Behav       Date:  2004-08       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.